Pharmacokinetic evaluation of sildenafil as a pulmonary hypertension treatment.


INTRODUCTION Sildenafil citrate is a potent, selective phosphodiesterase type 5 inhibitor approved for the treatment of pulmonary arterial hypertension (PAH) and plays an important role in the management of the disease. AREAS COVERED In this review, we focus on the current available information on the pharmacokinetics, pharmacodynamics, clinical efficacy… (More)
DOI: 10.1517/17425255.2013.804063

3 Figures and Tables


  • Blog articles referencing this paper

  • Presentations referencing similar topics